“In the community of rare diseases, DTRF has become known as a model of how patient advocates can power research through collaboration, making a significant impact on rare diseases and setting the standard for how the drug development process can be made better through direct and robust patient engagement at every level.”
HomeAbout DTRFNews & Updates
“In the community of rare diseases, DTRF has become known as a model of how patient advocates can power research through collaboration, making a significant impact on rare diseases and setting the standard for how the drug development process can be made better through direct and robust patient engagement at every level.”
John Whyte, MD, MPH, Chief Medical Officer
Stay Up to Date as We Uncover More About Desmoid Tumors